Melanoma-associated antigen C2 (307-315)

Melanoma-associated antigen C2 (307-315) is a synthetic peptide fragment derived from the MAGE-C2 protein, a member of the melanoma antigen gene family that is frequently overexpressed in various malignancies, notably melanoma. As a defined epitope corresponding to amino acids 307 through 315 of the MAGE-C2 sequence, this peptide is highly relevant in immunological research focused on tumor antigen recognition and T cell epitope mapping. Its precise structure allows for controlled studies of antigen presentation, immune activation, and peptide-MHC complex formation, thereby supporting a range of investigations into cancer immunology and antigen-specific immune responses.

Immunological assay development: The peptide serves as a critical tool in the development and optimization of immunoassays, such as ELISPOT, tetramer staining, and cytotoxicity assays, that evaluate antigen-specific T cell responses. By providing a well-characterized epitope, it enables researchers to assess the functional properties and specificity of T lymphocytes recognizing MAGE-C2-derived antigens. This is especially valuable for studies aiming to quantify immune reactivity or to monitor immune responses in preclinical research settings.

Antigen presentation studies: The defined sequence of this peptide facilitates in-depth analysis of peptide loading onto major histocompatibility complex (MHC) molecules. Researchers utilize it to investigate the mechanisms by which antigen-presenting cells process and present tumor-associated epitopes to cytotoxic T lymphocytes. Such studies are essential for elucidating the efficiency and selectivity of antigen presentation pathways, informing the design of targeted immunotherapies and vaccine constructs.

Epitope mapping and validation: The 307-315 fragment is instrumental in mapping immunodominant regions within the MAGE-C2 protein. By testing its ability to elicit T cell recognition, scientists can validate the immunogenicity of specific peptide sequences and delineate minimal epitopes required for effective immune activation. This approach supports the identification of candidate regions for future immunotherapeutic targeting and enhances understanding of tumor antigenicity.

Peptide-MHC structural analysis: The synthetic peptide is frequently used in studies that examine the structural basis of peptide-MHC interactions. Its defined sequence allows for co-crystallization or binding affinity assays with various MHC alleles, providing insights into the molecular determinants of T cell recognition. Structural analysis using this peptide informs the rational design of modified epitopes with improved stability or immunogenicity, contributing to the advancement of antigen engineering.

T cell receptor (TCR) specificity research: The MAGE-C2 (307-315) peptide is an invaluable reagent for dissecting the specificity and cross-reactivity of TCRs. By presenting this epitope in controlled experimental systems, researchers can analyze TCR recognition patterns, affinity thresholds, and potential for off-target effects. These studies are fundamental to the development of TCR-based immunotherapies and to the broader understanding of adaptive immune recognition in the context of tumor antigens.

1. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

2. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

3. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

4. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

5. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis